Influenza A virus vaccine H5N1 intranasal - BioDiem

Drug Profile

Influenza A virus vaccine H5N1 intranasal - BioDiem

Alternative Names: Avian (H5N1) intranasal influenza virus vaccine - BioDiem; Intranasal H5N1 influenza virus vaccine - BioDiem/Centers for Disease Control and Prevention

Latest Information Update: 15 Jan 2016

Price : $50

At a glance

  • Originator Institute of Experimental Medicine of the Russian Academy of Medical Sciences
  • Developer BioDiem; Centers for Disease Control and Prevention
  • Class Influenza A virus H5N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Influenza A virus H5N1 subtype

Most Recent Events

  • 15 Jan 2016 Phase-I development is ongoing
  • 31 Aug 2012 Phase-I clinical trials in Influenza-A virus H5N1 subtype in Russia (Intranasal)
  • 31 Aug 2012 Phase-I clinical trials in Influenza-A virus H5N1 subtype in Thailand (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top